See the DrugPatentWatch profile for Egrifta
What is Egrifta in Australia?
Egrifta is the brand name for tesamorelin, a medicine used to help reduce excess abdominal fat in certain people with HIV-associated lipodystrophy. In Australia, access is typically through specialist prescribing and the relevant hospital/pharmacy supply channel, rather than over-the-counter availability.
Is Egrifta approved for sale in Australia?
Whether Egrifta (tesamorelin) is currently listed/available on Australian formularies depends on the latest status with Australian regulators and listing arrangements. Availability can also vary by indication and prescriber type (for example, infectious disease or endocrinology specialists).
How do patients get Egrifta in Australia?
In practice, patients generally need:
- A diagnosis that matches the approved use (HIV-associated lipodystrophy and related fat accumulation).
- A specialist prescription.
- Arrangements for ongoing supply and monitoring through the treating team.
If you’re asking because you or someone else is trying to start treatment, the next step is usually confirming eligibility with the treating specialist and checking local supply through the prescribing pharmacy/hospital pathway.
What alternatives might be used instead in Australia?
If tesamorelin is not available, not listed for a particular patient, or unsuitable, clinicians may discuss other ways to manage HIV-associated fat changes (for example, lifestyle approaches, changes to antiretroviral regimen when appropriate, or other medications depending on the pattern of fat redistribution). The right option depends on the person’s specific symptoms and medical history.
What side effects or monitoring should people expect?
For tesamorelin, doctors typically monitor for medication-related effects and general safety while treatment is ongoing. The exact monitoring plan depends on the patient and clinical setting.
Tell me what you mean by “Egrifta australia”
If you share what you need—such as price/cost, how to get it, whether it’s available right now, or side effects and eligibility—I can answer more precisely for Australia.